Back to search results

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Folliculotropic Mycosis Fungoides · Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 · Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 · Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 · Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 · Transformed Mycosis Fungoides

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic, Scottsdale, Arizona, United States

    Contact: Study coordinator (Aaron Mangold, MD) · Mangold.Aaron@mayo.edu · 480-301-8484

  • City of Hope Medical Center, Duarte, California, United States

    Contact: Study coordinator (Christiane R. Querfeld) · cquerfeld@coh.org · 626-218-5822
    Contact: Principal Investigator (Christiane R. Querfeld)

  • Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

    Contact: Study coordinator (Pamela Allen, MD) · pamela.b.allen@emory.edu · 404-778-6195
Study leads

  • Christiane R Querfeld

    Principal Investigator

    City of Hope Medical Center

View source on ClinicalTrials.gov(opens in a new tab)